title: Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
abstract: J-104132 [(+)-(5S,6R, 7R)-2-butyl-7-[2-((2S)-2-carboxypropyl)-4-methoxyphenyl]-5-(3, 4-methylenedioxyphenyl)cyclopenteno[1,2-b]pyridine-6-carboxylic; also referred to as L-753,037] is a potent, selective inhibitor of ETA and ETB endothelin (ET) receptors (e.g., Ki: cloned human ETA = 0.034 nM; cloned human ETB = 0.104 nM). In both ligand-binding and isolated tissue preparation protocols, the inhibition of ET receptors with J-104132 is reversible and competitive. In vitro, J-104132 is a potent antagonist of ET-1-induced accumulation of [3H]inositol phosphates in Chinese hamster ovary cells stably expressing cloned human ETA receptors (IC50 = 0.059 nM), ET-1-induced contractions in rabbit iliac artery (pA2 = 9.70) and of BQ-3020-induced contractions in pulmonary artery (pA2 = 10.14). J-104132 is selective for ET receptors because it had no effect on contractions elicited by norepinephrine or KCl in the vascular preparations. The in vivo potency of J-104132 was assessed using challenges with exogenous ET-1. In conscious mice, 5 nmol/kg i.v. ET-1 causes death. Pretreatment with J-104132 prevents the lethal response to ET-1 when administered i.v. (ED50 = 0.045 mg/kg) or p.o. in fed animals (ED50 = 0.35 mg/kg). In conscious, normotensive rats, pressor responses to 0.5 nmol/kg i.v. ET-1 are inhibited by J-104132 after i.v. (0.1 mg/kg) or p.o. (1 mg/kg) administration. In anesthetized dogs, ET-1 was administered directly into the renal artery or brachial artery to generate dose-response (blood flow) curves, and the inhibitory potency of J-104132 (i.v. infusion) was quantified. J-104132 produced greater than 10-fold shifts in the ET-1 dose-response curves at 0.03 mg/kg/h (renal) and 0.3 mg/kg/h (brachial). Oral bioavailability of J-104132 in rats was approximately 40%. These studies indicate that J-104132 is a selective, potent, orally active antagonist of both ETA and ETB receptors and is an excellent pharmacological tool to explore the therapeutic use of a mixed ETA/ETB receptor antagonist.
authors.affiliation: Tsukuba Research Institutes and Development Research Laboratories, Banyu Pharmaceutical Co., Ltd., Ibaraki, Japan. niskbems@banyu.co.jp
authors.forename: M
authors.initials: M
authors.lastname: Nishikibe
authors.forename: H
authors.initials: H
authors.lastname: Ohta
authors.forename: M
authors.initials: M
authors.lastname: Okada
authors.forename: K
authors.initials: K
authors.lastname: Ishikawa
authors.forename: T
authors.initials: T
authors.lastname: Hayama
authors.forename: T
authors.initials: T
authors.lastname: Fukuroda
authors.forename: K
authors.initials: K
authors.lastname: Noguchi
authors.forename: M
authors.initials: M
authors.lastname: Saito
authors.forename: T
authors.initials: T
authors.lastname: Kanoh
authors.forename: S
authors.initials: S
authors.lastname: Ozaki
authors.forename: T
authors.initials: T
authors.lastname: Kamei
authors.forename: K
authors.initials: K
authors.lastname: Hara
authors.forename: D
authors.initials: D
authors.lastname: William
authors.forename: S
authors.initials: S
authors.lastname: Kivlighn
authors.forename: S
authors.initials: S
authors.lastname: Krause
authors.forename: R
authors.initials: R
authors.lastname: Gabel
authors.forename: G
authors.initials: G
authors.lastname: Zingaro
authors.forename: N
authors.initials: N
authors.lastname: Nolan
authors.forename: J
authors.initials: J
authors.lastname: O'Brien
authors.forename: F
authors.initials: F
authors.lastname: Clayton
authors.forename: J
authors.initials: J
authors.lastname: Lynch
authors.forename: D
authors.initials: D
authors.lastname: Pettibone
authors.forename: P
authors.initials: P
authors.lastname: Siegl
mesh_terms: D000818:Animals; D001667:Binding, Competitive; D001794:Blood Pressure / Q000187:drug effects*; D016466:CHO Cells; D003001:Cloning, Molecular; D006224:Cricetinae; D004285:Dogs; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000378:metabolism; D005260:Female; D006624:Hippocampus / Q000502:physiology; D006801:Humans; D007083:Iliac Artery / Q000187:drug effects / Q000502:physiology; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D010716:Phosphatidylinositols / Q000378:metabolism; D011651:Pulmonary Artery / Q000187:drug effects / Q000502:physiology; D011725:Pyridines / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000235:genetics; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D012077:Renal Artery / Q000187:drug effects / Q000502:physiology; D014162:Transfection; D014599:Uterus / Q000502:physiology
chemical_list: D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D010716:Phosphatidylinositols; D011725:Pyridines; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin; D011994:Recombinant Proteins; C119319:J 104132